Back to blog

Are you investing in the farm business? You should know that covid is not pulling anymore, obesity is in

The last three years have shown how quickly the situation can change, not only in the stock market as a whole, but also within a single sector. While as recently as the turn of 2020 and 2021, investments in shares of pharmaceutical companies focused on the development and delivery of an effective and safe vaccine against the SARS-CoV-2 coronavirus seemed promising, today completely different companies are leading the way within the pharmaceutical sector.

Are you investing in the farm business? You should know that covid is not pulling anymore, obesity is in

Moderna, Pfizer, BioNTech, but also AstraZeneca and Novavax. These are the pharmaceutical companies that, after the outbreak of the coronavirus pandemic, literally rushed to develop a vaccine against the virus that has claimed several million lives worldwide. And many of these companies have celebrated success, which has duly reflected in the rise of their market value.

But as the pandemic faded, the world began to return to normal, and with it, the interest in the shares of companies that had worked on the coronavirus and everything around it gradually declined. Perhaps this development is most evident in the biotechnology company Moderna. Its shares could be bought for around $20 at the beginning of 2020. But in just 20 months, their value has risen to $450, a 22.5-fold increase. *

Today, a Moderna share can be bought for $70.* In addition, Moderna is experiencing a big drop in sales and is operating in the red. The main reason for this is that Moderna has not yet been able to capitalize on the knowledge gained during the cover-up elsewhere and seems to be missing the train.

Snímek obrazovky 2023-11-20 v 10.34.36

Moderna Inc's share price performance over the last 5 years (source: www.investing.com)*

But that doesn't mean that investors should disregard the pharmaceutical sector as a whole. In fact, the Covid pandemic has only temporarily drowned out another pandemic that, while not infectious, is spreading as quickly as respiratory viruses. The world (especially the developed world) has been facing an obesity pandemic for many years. Hand in hand with obesity is the spread of diabetes.

It is on a cure for diabetes that the Danish pharmaceutical company Novo Nordisk is betting. It is one of the most successful pharmaceutical companies in the world and one of the most valuable European companies ever. Its success is likely to be compounded, as Novo Nordisk has recently come up with products that can significantly reduce body weight. These are the prescription drugs Wegova and Ozempic.

Similar products are or will be marketed by the US pharmaceutical group Eli Lilly. Although its drug Mounjaro is intended for the treatment of diabetes, it can also reduce weight. In addition, a few days ago, the US Food and Drug Administration (FDA) approved Eli Lilly's weight-loss drug, which will be available on the market under the name Zepbond.

The shares of both companies are thus flying upwards. Eli Lilly is up nearly 64 percent since the beginning of this year, and Novo Nordisk shares have added nearly 47 percent.* Eli Lilly's market capitalization currently stands at more than $567 billion, making the company more than $200 billion more valuable than the world's largest and most valuable pharmaceutical group, Johnson & Johnson, until recently. Novo Nordisk is already closing in on Johnson & Johnson.

Snímek obrazovky 2023-11-20 v 10.35.31

Eli Lilly and Company's share price performance over the last 5 years (source: www.investing.com)*

Snímek obrazovky 2023-11-20 v 10.36.21

Novo Nordisk A/S share price development over the last 5 years (source: www.investing.com)*

It might seem like a bad time to invest in shares of either Eli Lilly or Novo Nordisk. The fact is, of course, that those who invested at least at the beginning of this year have undoubted reason to rejoice. But that does not mean that such an investment would not be worth considering now. The market for obesity drugs is at the very beginning of its growth. According to the US investment bank Goldman Sachs, this market will be worth around six billion dollars this year. But it is set to grow to at least $100 billion by the end of this decade.[1] It is therefore very likely that Novo Nordisk and Eli Lilly will both have a significant share of the market. Even with this, the obesitology segment will be attractive for other players to enter. However, Novo Nordisk and Eli Lilly have a big head start so far.

---

* Past performance is no guarantee of future results.

[1] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or on the current economic environment, which may change. Such statements are not guarantees of future performance. They involve risks and other uncertainties that are difficult to predict. Results may differ materially from those expressed or implied by any forward-looking statements.

Read more

Bitcoin Breaks Records, "Trump Rally" Also Dominates the Crypto World

Bitcoin Breaks Records, "Trump Rally" Also Dominates the Crypto World

The post-election market rally, which took over U.S. markets, has spilled over into the cryptocurrency world, with Bitcoin setting new records nearly every day.* Investors who had previously avoided these assets found an opportunity to explore them in 2024 through newly launched Bitcoin-associated Exchange Traded Funds (ETFs). The largest of these, the iShares Bitcoin Trust by financial assets manager BlackRock, has already surpassed the volume of the renowned gold-tracking fund.

Spotify Successfully Cuts Costs, Expects Surprising Revenue and Subscriber Growth

Spotify Successfully Cuts Costs, Expects Surprising Revenue and Subscriber Growth

Swedish giant Spotify, owner of the world's largest music streaming platform, has more than doubled its market value this year.* This achievement is primarily attributed to its successful cost-cutting strategies and price increases, while maintaining impressive growth in its user base. Although its latest financial results slightly missed market expectations, Spotify's outlook for the current quarter is more than optimistic, underscoring the continuation of trends that have contributed to the consistent performance of its stock.

Donald Trump’s Second Term and Commodity Market Opportunities

Donald Trump’s Second Term and Commodity Market Opportunities

Donald Trump’s second presidency in the White House could bring significant shifts not only to stock markets but also to the commodities sector, particularly oil, natural gas, and metals. Known for his inclination to fossil fuels, the future U.S. president is expected to reduce green economy regulations, which could lead to notable developments in these markets.

Trump's election victory: What can be expected from the capital markets?

Trump's election victory: What can be expected from the capital markets?

The U.S. presidential elections were held on November 5, 2024, and the winner is Donald Trump. Even before the official results were announced, as it became clear he was dominating in key battleground states, the so-called "Trump stocks" saw a significant surge. The outlook for his presidency over the next four years could bring potential tax policy loosening or increased support for large corporations and the domestic economy. However, risks are evident in Trump's stance on foreign trade.